MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.980
-0.050
-1.24%
Opening 13:37 01/15 EST
OPEN
4.040
PREV CLOSE
4.030
HIGH
4.110
LOW
3.910
VOLUME
1.63M
TURNOVER
--
52 WEEK HIGH
9.02
52 WEEK LOW
0.8800
MARKET CAP
337.94M
P/E (TTM)
-3.2222
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Technologies for Delivery of Proteins, Antibodies and Nucleic Acids Market 2021 to 2024 Production, Value (USD), Share by Region Like North America, Europe, China, Japan, Middle East & Africa, India, South 360 Market Updates
Jan 14, 2021 (The Expresswire) -- Global“Technologies for Delivery of Proteins, Antibodies and Nucleic AcidsMarket” Report 2021 - 2024 delivers the latest...
The Express Wire · 1d ago
Global RNAi Technology Market 2020 Upcoming Trends, Latest Innovation, Advance Technology and Top Companies to 2025
Jan 13, 2021 (CDN Newswire via Comtex) -- The latest informative study entitled Global RNAi Technology Market 2020 by Company, Regions, Type and Application,...
CDN Newswire · 2d ago
Global Antisense Therapy Market Size Study with COVID-19 Impact 2020 Research Strategies and Forecast to 2025
Jan 13, 2021 (CDN Newswire via Comtex) -- Global Antisense Therapy Market 2020 by Company, Type and Application, Forecast to 2025 published via...
CDN Newswire · 2d ago
Global Antisense Therapy Market 2020 Competitive Dynamics, Growth Analysis, Segmentation and Worldwide Players Strategies up to 2025
Jan 13, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has added a new report Global Antisense Therapy Market 2020 by Company, Regions, Type and...
CDN Newswire · 2d ago
Hepatitis B Treatment Market 2020: Company Profiles, Global Segments, Size, Landscape, Demand and Recent Trends by Forecast to 2023
Heraldkeepers · 3d ago
Global Next-Generation Batteries Market Analysis, Size, Share, Growth, Trends and Forecast 2025
Jan 11, 2021 (Market Insight Reports) -- Selbyville, Delaware Metabolic Syndrome Market research now available at Market Study Report encompasses an...
Market Insight Reports · 3d ago
Global RNAi for Therapeutic Market Outlook 2021: Market Trends, Segmentation, consumption by Regional data, Market Growth and Competitive Landscape
Jan 11, 2021 (The Expresswire) -- RNAi for Therapeutic Market provides detailed analysis of Market Overview, Drivers, Prospects, Potential Application. Also...
The Express Wire · 4d ago
AY, ABUS, ACLS and FIXX among after-hours movers
Gainers: [[VIVO]] +6%. [[ABUS]] +4.6%. [[AY]] +4.2%. [[EBON]] +3.5%. [[TSE]] +3.4%.Losers: [[ACLS]] -14%. [[DOGZ]] -8.5%. [[HX]] -7.8%. [[FIXX]] -5.9%. [[JRJC]] -2.1%.
Seekingalpha · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABUS. Analyze the recent business situations of Arbutus Biopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABUS stock price target is 7.00 with a high estimate of 10.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 113
Institutional Holdings: 26.64M
% Owned: 31.38%
Shares Outstanding: 84.91M
TypeInstitutionsShares
Increased
9
1.37M
New
45
5.91M
Decreased
16
9.25M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.29%
Pharmaceuticals & Medical Research
+0.28%
Key Executives
Chairman/Independent Director
Frank Torti
President/Chief Executive Officer/Director
William Collier
Chief Financial Officer
David Hastings
Executive Vice President/Chief Compliance Officer/General Counsel
Elizabeth Howard
Chief Scientific Officer
Michael Sofia
Other
Michael McElhaugh
Other
Gaston Picchio
Independent Director
Daniel Burgess
Independent Director
Andrew Cheng
Independent Director
Richard Henriques
Independent Director
Keith Manchester
Independent Director
James Meyers
Independent Director
Eric Venker
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing cure for people with chronic hepatitis B virus (HBV) infection. Its product pipeline is focused on finding curative combination regimen for chronic HBV infection, with the objective of developing a suite of products that intervene at different points in the viral life cycle and reactivate the host immune system. It is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. The Company’s HBV product pipeline includes ribonucleic acid (RNA) interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit programmed death-ligand one (PDL1) and oral HBV RNA destabilizers. Its subsidiaries include Arbutus Inc and Arbutus Biopharma US Holdings, Inc.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Arbutus Biopharma Corp stock information, including NASDAQ:ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.